PDF(Pubmed)
Abstract：
Hexahydrocannabinol (HHC), 6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol, is a semi-synthetic cannabinoid that has presented challenges to analytical laboratories due to its emergence and spread in the drug market. The lack of information on human pharmacokinetics hinders the development and application of presumptive and confirmatory tests for reliably detecting HHC consumption. To address this knowledge gap, we report the analytical results obtained from systematic forensic toxicological analysis of body-fluid samples collected from three individuals suspected of drug-impaired driving after HHC consumption. Urine and plasma samples were analyzed using non-targeted liquid chromatography-high-resolution tandem mass spectrometry. The results provided evidence that HHC undergoes biotransformation reactions similar to other well-characterized cannabinoids, such as ∆9-tetrahydrocannabinol or cannabidiol. Notably, HHC itself was only detectable in plasma samples, not in urine samples. The observed Phase I reactions involved oxidation of C11 and the pentyl side chain, leading to corresponding hydroxylated and carboxylic acid species. Additionally, extensive glucuronidation of HHC and its Phase I metabolites was evident.
摘要：
六氢大麻酚（HHC），6,6,9-三甲基-3-戊基-6a，7,8,9,10,10a-六氢苯并[c]色烯-1-醇，是一种半合成大麻素，由于其在药物市场的出现和传播，对分析实验室提出了挑战。缺乏有关人体药代动力学的信息阻碍了可靠检测HHC消耗的推定和确认测试的开发和应用。为了解决这个知识差距，我们报告了对3名疑似服用HHC后药物损害驾驶的患者体液样本进行系统的法医毒理学分析的结果.使用非靶向液相色谱-高分辨率串联质谱法分析尿液和血浆样品。结果提供了证据，表明HHC经历了类似于其他特征明确的大麻素的生物转化反应，如Δ9-四氢大麻酚或大麻二酚。值得注意的是,HHC本身仅在血浆样本中检测到，不在尿液样本中。观察到的第一阶段反应涉及C11和戊基侧链的氧化，导致相应的羟基化和羧酸种类。此外,HHC及其I相代谢物的广泛葡糖醛酸化是明显的。
